Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 8 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 3 weeks ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 7 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 11 months ago

Prevention & Chronic Conditions
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 1 month ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 7 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 2 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions